Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Therapeutic effect of Active Hexose-Correlated Compound (AHCC) combined with CpG-ODN (oligodeoxynucleotide) in B16 melanoma murine model.

Ignacio RM, Kim CS, Kim YD, Lee HM, Qi XF, Kim SK.

Cytokine. 2015 Dec;76(2):131-137. doi: 10.1016/j.cyto.2015.06.002. Epub 2015 Jun 13.

PMID:
26082022
2.

Cancer immunotherapeutic effects of novel CpG ODN in murine tumor model.

Cho HC, Kim BH, Kim K, Park JY, Chang JH, Kim SK.

Int Immunopharmacol. 2008 Oct;8(10):1401-7. doi: 10.1016/j.intimp.2008.05.010. Epub 2008 Jun 18.

PMID:
18687302
3.

Active hexose correlated compound enhances tumor surveillance through regulating both innate and adaptive immune responses.

Gao Y, Zhang D, Sun B, Fujii H, Kosuna K, Yin Z.

Cancer Immunol Immunother. 2006 Oct;55(10):1258-66. Epub 2005 Dec 16.

PMID:
16362410
4.

CpG immunostimulatory oligodeoxynucleotide 1826 enhances antitumor effect of interleukin 12 gene-modified tumor vaccine in a melanoma model in mice.

Switaj T, Jalili A, Jakubowska AB, Drela N, Stoksik M, Nowis D, Basak G, Golab J, Wysocki PJ, Mackiewicz A, Sasor A, Socha K, Jakóbisiak M, Lasek W.

Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4165-75.

5.

Synergistic antitumor effects of CpG oligodeoxynucleotide and STAT3 inhibitory agent JSI-124 in a mouse melanoma tumor model.

Molavi O, Ma Z, Hamdy S, Lai R, Lavasanifar A, Samuel J.

Immunol Cell Biol. 2008 Aug-Sep;86(6):506-14. doi: 10.1038/icb.2008.27. Epub 2008 Apr 8.

PMID:
18392040
7.

Encapsulation in liposomal nanoparticles enhances the immunostimulatory, adjuvant and anti-tumor activity of subcutaneously administered CpG ODN.

de Jong S, Chikh G, Sekirov L, Raney S, Semple S, Klimuk S, Yuan N, Hope M, Cullis P, Tam Y.

Cancer Immunol Immunother. 2007 Aug;56(8):1251-64. Epub 2007 Jan 23.

PMID:
17242927
8.

CpG oligonucleotide therapy cures subcutaneous and orthotopic tumors and evokes protective immunity in murine bladder cancer.

Ninalga C, Loskog A, Klevenfeldt M, Essand M, Tötterman TH.

J Immunother. 2005 Jan-Feb;28(1):20-7.

PMID:
15614041
9.

Anti-tumor activity of CpG-ODN aerosol in mouse lung metastases.

Sfondrini L, Sommariva M, Tortoreto M, Meini A, Piconese S, Calvaruso M, Van Rooijen N, Bonecchi R, Zaffaroni N, Colombo MP, Tagliabue E, Balsari A.

Int J Cancer. 2013 Jul 15;133(2):383-93. doi: 10.1002/ijc.28028. Epub 2013 Feb 12.

10.

CpG oligodeoxynucleotide induces apoptosis and cell cycle arrest in A20 lymphoma cells via TLR9-mediated pathways.

Qi XF, Zheng L, Kim CS, Lee KJ, Kim DH, Cai DQ, Qin JW, Yu YH, Wu Z, Kim SK.

Mol Immunol. 2013 Jul;54(3-4):327-37. doi: 10.1016/j.molimm.2013.01.001. Epub 2013 Jan 26.

PMID:
23357786
11.

Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs.

Ballas ZK, Krieg AM, Warren T, Rasmussen W, Davis HL, Waldschmidt M, Weiner GJ.

J Immunol. 2001 Nov 1;167(9):4878-86.

12.

Active Hexose Correlated Compound (AHCC) promotes an intestinal immune response in BALB/c mice and in primary intestinal epithelial cell culture involving toll-like receptors TLR-2 and TLR-4.

Mallet JF, Graham É, Ritz BW, Homma K, Matar C.

Eur J Nutr. 2016 Feb;55(1):139-46. doi: 10.1007/s00394-015-0832-2. Epub 2015 Jan 18.

PMID:
25596849
13.

Active Hexose Correlated Compound Activates Immune Function to Decrease Chlamydia trachomatis Shedding in a Murine Stress Model.

Belay T, Fu CL, Woart A.

J Nutr Med Diet Care. 2015;1(1). pii: JNMDC-1-006. Epub 2015 Sep 15.

14.

CpG oligodeoxynucleotide 1826 enhances the Lewis lung cancer response to radiotherapy in murine tumor.

Yuan S, Qiao T, Chen W.

Cancer Biother Radiopharm. 2011 Apr;26(2):203-8. doi: 10.1089/cbr.2010.0871.

PMID:
21539452
15.

Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages.

Buhtoiarov IN, Sondel PM, Wigginton JM, Buhtoiarova TN, Yanke EM, Mahvi DA, Rakhmilevich AL.

Immunology. 2011 Feb;132(2):226-39. doi: 10.1111/j.1365-2567.2010.03357.x. Epub 2010 Oct 13.

16.

Immunological effect of active hexose correlated compound (AHCC) in healthy volunteers: a double-blind, placebo-controlled trial.

Terakawa N, Matsui Y, Satoi S, Yanagimoto H, Takahashi K, Yamamoto T, Yamao J, Takai S, Kwon AH, Kamiyama Y.

Nutr Cancer. 2008;60(5):643-51. doi: 10.1080/01635580801993280.

PMID:
18791928
17.

Induction of interleukin-6 and interleukin-12 in bovine B lymphocytes, monocytes, and macrophages by a CpG oligodeoxynucleotide (ODN 2059) containing the GTCGTT motif.

Zhang Y, Shoda LK, Brayton KA, Estes DM, Palmer GH, Brown WC.

J Interferon Cytokine Res. 2001 Oct;21(10):871-81.

PMID:
11711000
18.

Liposomal CpG-ODN: An in vitro and in vivo study on macrophage subtypes responses, biodistribution and subsequent therapeutic efficacy in mice models of cancers.

Nikoofal-Sahlabadi S, Matbou Riahi M, Sadri K, Badiee A, Nikpoor AR, Jaafari MR.

Eur J Pharm Sci. 2018 Jul 1;119:159-170. doi: 10.1016/j.ejps.2018.04.018. Epub 2018 Apr 13.

PMID:
29660463
19.
20.

CpG-Oligodeoxynucleotides activate tyrosinase-related protein 2-specific T lymphocytes but do not lead to a protective tumor-specific memory response.

Sfondrini L, Besusso D, Bronte V, Macino B, Rossini A, Colombo MP, Ménard S, Balsari A.

Cancer Immunol Immunother. 2004 Aug;53(8):697-704. Epub 2004 Mar 18.

PMID:
15034674

Supplemental Content

Support Center